soosoo
2021-12-22
Good sharing
S. Korea begins review of Pfizer's oral COVID-19 pill<blockquote>韩国开始审查辉瑞口服 COVID-19 药丸</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
5
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":691125672,"tweetId":"691125672","gmtCreate":1640153102058,"gmtModify":1640153102425,"author":{"id":4089777453696550,"idStr":"4089777453696550","authorId":4089777453696550,"authorIdStr":"4089777453696550","name":"soosoo","avatar":"https://static.tigerbbs.com/a7a8e4a0c1e8d4b7bf1e9db91cfaffc8","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":20,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>Good sharing</p></body></html>","htmlText":"<html><head></head><body><p>Good sharing</p></body></html>","text":"Good sharing","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/691125672","repostId":1188384720,"repostType":4,"repost":{"id":"1188384720","kind":"news","pubTimestamp":1640152952,"share":"https://www.laohunote.com/m/news/1188384720?lang=zh_CN&edition=full","pubTime":"2021-12-22 14:02","market":"us","language":"en","title":"S. Korea begins review of Pfizer's oral COVID-19 pill<blockquote>韩国开始审查辉瑞口服 COVID-19 药丸</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1188384720","media":"Yonhap","summary":"SEOUL, Dec. 22 (Yonhap) -- South Korea's drug safety agency said Wednesday that it has begun reviewi","content":"<p>SEOUL, Dec. 22 (Yonhap) -- South Korea's drug safety agency said Wednesday that it has begun reviewing an emergency authorization of U.S. drug giant Pfizer Inc.'s oral drug to treat COVID-19.</p><p><blockquote>韩联社首尔12月22日电韩国药品安全局周三表示，已开始审查美国制药巨头辉瑞公司治疗新冠肺炎的口服药物的紧急授权。</blockquote></p><p> Paxlovid is the antiviral pill for the treatment of mild to moderate COVID-19 in patients at increased risk of hospitalization or death, according to Pfizer and the Ministry of Food and Drug Safety.</p><p><blockquote>根据辉瑞公司和食品药品安全部的说法，Paxlovid是一种抗病毒药物，用于治疗住院或死亡风险增加的患者的轻度至中度新冠肺炎。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f5435876a060de363e87a33887064854\" tg-width=\"500\" tg-height=\"324\" width=\"100%\" height=\"auto\"><span>The Ministry of Food and Drug Safety (PHOTO NOT FOR SALE) (Yonhap)</span></p><p><blockquote><p class=\"t-img-caption\"><span>食品药品安全部（照片非卖品）（韩联社）</span></p></blockquote></p><p> If authorized, Paxlovid would be the first oral antiviral of its kind in South Korea.</p><p><blockquote>如果获得批准，Paxlovid将成为韩国第一个口服抗病毒药物。</blockquote></p><p> The drug candidate is a protease inhibitor antiviral therapy that is specifically designed to be administered orally so that it can be prescribed at the first sign of infection or at first awareness of an exposure.</p><p><blockquote>候选药物是一种蛋白酶抑制剂抗病毒疗法，其专门设计为口服给药，以便在感染的第一个迹象或首次意识到暴露时可以开出处方。</blockquote></p><p> The U.S. Food and Drug Administration is poised to grant an Emergency Use Authorization approval of Paxlovid along with Merck & Co.'s pill this week, according to multiple media reports.</p><p><blockquote>美国据多家媒体报道，美国食品和药物管理局准备在本周批准 Paxlovid 和默克公司的药丸的紧急使用授权。</blockquote></p><p> Pfizer said its trial results showed Paxlovid reduces by 89 percent the risk of hospitalization or death in patients at high risk of severe illness within three days of the onset of COVID-19 symptoms.</p><p><blockquote>辉瑞公司表示，其试验结果显示，在出现 COVID-19 症状后三天内，Paxlovid 可将重症高风险患者住院或死亡的风险降低 89%。</blockquote></p><p></p>","source":"lsy1640152899971","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S. Korea begins review of Pfizer's oral COVID-19 pill<blockquote>韩国开始审查辉瑞口服 COVID-19 药丸</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS. Korea begins review of Pfizer's oral COVID-19 pill<blockquote>韩国开始审查辉瑞口服 COVID-19 药丸</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Yonhap</strong><span class=\"h-time small\">2021-12-22 14:02</span>\n</p>\n</h4>\n</header>\n<article>\n<p>SEOUL, Dec. 22 (Yonhap) -- South Korea's drug safety agency said Wednesday that it has begun reviewing an emergency authorization of U.S. drug giant Pfizer Inc.'s oral drug to treat COVID-19.</p><p><blockquote>韩联社首尔12月22日电韩国药品安全局周三表示，已开始审查美国制药巨头辉瑞公司治疗新冠肺炎的口服药物的紧急授权。</blockquote></p><p> Paxlovid is the antiviral pill for the treatment of mild to moderate COVID-19 in patients at increased risk of hospitalization or death, according to Pfizer and the Ministry of Food and Drug Safety.</p><p><blockquote>根据辉瑞公司和食品药品安全部的说法，Paxlovid是一种抗病毒药物，用于治疗住院或死亡风险增加的患者的轻度至中度新冠肺炎。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f5435876a060de363e87a33887064854\" tg-width=\"500\" tg-height=\"324\" width=\"100%\" height=\"auto\"><span>The Ministry of Food and Drug Safety (PHOTO NOT FOR SALE) (Yonhap)</span></p><p><blockquote><p class=\"t-img-caption\"><span>食品药品安全部（照片非卖品）（韩联社）</span></p></blockquote></p><p> If authorized, Paxlovid would be the first oral antiviral of its kind in South Korea.</p><p><blockquote>如果获得批准，Paxlovid将成为韩国第一个口服抗病毒药物。</blockquote></p><p> The drug candidate is a protease inhibitor antiviral therapy that is specifically designed to be administered orally so that it can be prescribed at the first sign of infection or at first awareness of an exposure.</p><p><blockquote>候选药物是一种蛋白酶抑制剂抗病毒疗法，其专门设计为口服给药，以便在感染的第一个迹象或首次意识到暴露时可以开出处方。</blockquote></p><p> The U.S. Food and Drug Administration is poised to grant an Emergency Use Authorization approval of Paxlovid along with Merck & Co.'s pill this week, according to multiple media reports.</p><p><blockquote>美国据多家媒体报道，美国食品和药物管理局准备在本周批准 Paxlovid 和默克公司的药丸的紧急使用授权。</blockquote></p><p> Pfizer said its trial results showed Paxlovid reduces by 89 percent the risk of hospitalization or death in patients at high risk of severe illness within three days of the onset of COVID-19 symptoms.</p><p><blockquote>辉瑞公司表示，其试验结果显示，在出现 COVID-19 症状后三天内，Paxlovid 可将重症高风险患者住院或死亡的风险降低 89%。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://en.yna.co.kr/view/AEN20211222004300320?section=search\">Yonhap</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://en.yna.co.kr/view/AEN20211222004300320?section=search","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188384720","content_text":"SEOUL, Dec. 22 (Yonhap) -- South Korea's drug safety agency said Wednesday that it has begun reviewing an emergency authorization of U.S. drug giant Pfizer Inc.'s oral drug to treat COVID-19.\nPaxlovid is the antiviral pill for the treatment of mild to moderate COVID-19 in patients at increased risk of hospitalization or death, according to Pfizer and the Ministry of Food and Drug Safety.\nThe Ministry of Food and Drug Safety (PHOTO NOT FOR SALE) (Yonhap)\nIf authorized, Paxlovid would be the first oral antiviral of its kind in South Korea.\nThe drug candidate is a protease inhibitor antiviral therapy that is specifically designed to be administered orally so that it can be prescribed at the first sign of infection or at first awareness of an exposure.\nThe U.S. Food and Drug Administration is poised to grant an Emergency Use Authorization approval of Paxlovid along with Merck & Co.'s pill this week, according to multiple media reports.\nPfizer said its trial results showed Paxlovid reduces by 89 percent the risk of hospitalization or death in patients at high risk of severe illness within three days of the onset of COVID-19 symptoms.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2888,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":11,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/691125672"}
精彩评论